This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stamatos, N. M.
Right arrow Articles by VanCott, T. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stamatos, N. M.
Right arrow Articles by VanCott, T. C.

 Previous Article  |  Next Article 

Journal of Virology, December 1998, p. 9656-9667, Vol. 72, No. 12
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Neutralizing Antibodies from the Sera of Human Immunodeficiency Virus Type 1-Infected Individuals Bind to Monomeric gp120 and Oligomeric gp140

Nicholas M. Stamatos,1,dagger John R. Mascola,1,3 Vaniambadi S. Kalyanaraman,4 Mark K. Louder,2 Lynn M. Frampton,2 Deborah L. Birx,1 and Thomas C. VanCott2,*

Division of Retrovirology, Walter Reed Army Institute of Research,1 and Henry M. Jackson Foundation,2 Rockville, Maryland 20850; Department of Infectious Diseases, Naval Medical Research Institute, Bethesda, Maryland 208893; and Advanced BioScience Laboratories, Kensington, Maryland 208954

Received 1 July 1998/Accepted 9 September 1998

Antibodies that neutralize primary isolates of human immunodeficiency virus type 1 (HIV-1) appear during HIV-1 infection but are difficult to elicit by immunization with current vaccine products comprised of monomeric forms of HIV-1 envelope glycoprotein gp120. The limited neutralizing antibody response generated by gp120 vaccine products could be due to the absence or inaccessibility of the relevant epitopes. To determine whether neutralizing antibodies from HIV-1-infected patients bind to epitopes accessible on monomeric gp120 and/or oligomeric gp140 (ogp140), purified total immunoglobulin from the sera of two HIV-1-infected patients as well as pooled HIV immune globulin were selectively depleted of antibodies which bound to immobilized gp120 or ogp140. After passage of each immunoglobulin preparation through the respective columns, antibody titers against gp120 and ogp140 were specifically reduced at least 128-fold. The gp120- and gp140-depleted antibody fraction from each serum displayed reduced neutralization activity against three primary and two T-cell line-adapted (TCLA) HIV-1 isolates. Significant residual neutralizing activity, however, persisted in the depleted sera, indicating additional neutralizing antibody specificities. gp120- and ogp140-specific antibodies eluted from each column neutralized both primary and TCLA viruses. These data demonstrate the presence and accessibility of epitopes on both monomeric gp120 and ogp140 that are specific for antibodies that are capable of neutralizing primary isolates of HIV-1. Thus, the difficulties associated with eliciting neutralizing antibodies by using current monomeric gp120 subunit vaccines may be related less to improper protein structure and more to ineffective immunogen formulation and/or presentation.

* Corresponding author. Mailing address: Henry M. Jackson Foundation, 13 Taft Ct., Suite 200, Rockville, MD 20850. Phone: (301) 762-0089. Fax: (301) 762-4177. E-mail: tvancott{at}hiv.hjf.org.

dagger Present address: Institute of Human Virology and Department of Medicine, University of Maryland, Baltimore, MD 21201-1192.

Journal of Virology, December 1998, p. 9656-9667, Vol. 72, No. 12
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Krachmarov, C., Pinter, A., Honnen, W. J., Gorny, M. K., Nyambi, P. N., Zolla-Pazner, S., Kayman, S. C. (2005). Antibodies That Are Cross-Reactive for Human Immunodeficiency Virus Type 1 Clade A and Clade B V3 Domains Are Common in Patient Sera from Cameroon, but Their Neutralization Activity Is Usually Restricted by Epitope Masking. J. Virol. 79: 780-790 [Abstract] [Full Text]  
  • Srivastava, I. K., Stamatatos, L., Legg, H., Kan, E., Fong, A., Coates, S. R., Leung, L., Wininger, M., Donnelly, J. J., Ulmer, J. B., Barnett, S. W. (2002). Purification and Characterization of Oligomeric Envelope Glycoprotein from a Primary R5 Subtype B Human Immunodeficiency Virus. J. Virol. 76: 2835-2847 [Abstract] [Full Text]  
  • Zang, X., Atmadja, A. K., Gray, P., Allen, J. E., Gray, C. A., Lawrence, R. A., Yazdanbakhsh, M., Maizels, R. M. (2000). The Serpin Secreted by Brugia malayi Microfilariae, Bm-SPN-2, Elicits Strong, but Short-Lived, Immune Responses in Mice and Humans. J. Immunol. 165: 5161-5169 [Abstract] [Full Text]  
  • Doranz, B. J., Baik, S. S. W., Doms, R. W. (1999). Use of a gp120 Binding Assay To Dissect the Requirements and Kinetics of Human Immunodeficiency Virus Fusion Events. J. Virol. 73: 10346-10358 [Abstract] [Full Text]  
  • VanCott, T. C., Mascola, J. R., Loomis-Price, L. D., Sinangil, F., Zitomersky, N., McNeil, J., Robb, M. L., Birx, D. L., Barnett, S. (1999). Cross-Subtype Neutralizing Antibodies Induced in Baboons by a Subtype E gp120 Immunogen Based on an R5 Primary Human Immunodeficiency Virus Type 1 Envelope. J. Virol. 73: 4640-4650 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»